Valuation: BioNTech SE

Market Cap 21.35B 120B 24.05B 19.98B 18.11B 34.2B 2,318B 34.44B 240B 93.32B 1,183B 90.27B 88.33B 3,802B P/E 2026 *
-14.9x
P/E 2027 * -15.6x
Enterprise Value 9.98B 55.98B 11.24B 9.34B 8.46B 15.98B 1,084B 16.1B 112B 43.62B 553B 42.19B 41.29B 1,777B EV / Sales 2026 *
5.52x
EV / Sales 2027 * 6.25x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-3.00%
1 week-7.38%
Current month-6.86%
1 month-9.11%
3 months-2.08%
6 months+1.54%
Current year-9.41%
1 week 29.73
Extreme 29.73
32.15
1 month 29.73
Extreme 29.73
34.15
Current year 25.78
Extreme 25.78
41
1 year 25.78
Extreme 25.78
41
3 years 25.78
Extreme 25.78
49.05
5 years 25.78
Extreme 25.78
66.08
10 years 25.78
Extreme 25.78
66.08
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 61 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 56 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.00%-7.38% - - 24.05B
+4.16%+4.16%+49.37%+94.17% 74.69B
0.00%-1.42%+22.95%+78.76% 58.81B
+0.36%+0.49%+7.00%+34.73% 48.45B
-3.76%-2.25%+329.09%+698.20% 42.84B
-2.30%-3.35%+26.81%+30.88% 42.79B
+0.31%-0.68%+5.30%+108.64% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
-1.96%-2.88%-8.97%-13.92% 24.05B
Average -0.84%-0.25%+52.86%+123.38% 43.81B
Weighted average by Cap. -0.25%-0.54%+55.72%+129.76%

Financials

2026 *2027 *
Net sales 1.81B 10.14B 2.04B 1.69B 1.53B 2.89B 196B 2.92B 20.31B 7.9B 100B 7.64B 7.48B 322B 1.81B 10.16B 2.04B 1.69B 1.54B 2.9B 197B 2.92B 20.35B 7.91B 100B 7.66B 7.49B 322B
Net income -1.38B -7.72B -1.55B -1.29B -1.17B -2.21B -149B -2.22B -15.47B -6.02B -76.26B -5.82B -5.7B -245B -1.31B -7.35B -1.48B -1.23B -1.11B -2.1B -142B -2.12B -14.74B -5.73B -72.63B -5.54B -5.42B -233B
Net Debt -11.37B -63.77B -12.81B -10.64B -9.64B -18.21B -1,235B -18.34B -128B -49.7B -630B -48.07B -47.04B -2,025B -10.03B -56.25B -11.3B -9.38B -8.51B -16.06B -1,089B -16.18B -113B -43.84B -556B -42.4B -41.49B -1,786B
Projected Income Statement - Annual - BioNTech SE
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
06/10/26 R$29.73 -3.00% 670
05/10/26 R$30.65 -2.98% 969
02/10/26 R$31.59 -0.38% 3,959
01/10/26 R$31.71 -0.66% 2,215
30/09/26 R$31.92 -0.56% 136
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Ratings Surperformance© - BioNTech SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
84.98EUR
Average target price
103.36EUR
Spread / Average Target
+21.63%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BioNTech SE